Take­da fo­cus­es on ‘di­verse’ pipeline prospects on heels of two ac­qui­si­tions

Af­ter a whop­ping $4 bil­lion as­set buy from Nim­bus Ther­a­peu­tics, along with a $400 mil­lion deal with Hutchmed for a col­orec­tal can­cer drug, Take­da ex­ec­u­tives …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER